Meena Okera

3.8k total citations · 2 hit papers
32 papers, 2.0k citations indexed

About

Meena Okera is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Meena Okera has authored 32 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Meena Okera's work include Advanced Breast Cancer Therapies (21 papers), Cancer Treatment and Pharmacology (11 papers) and HER2/EGFR in Cancer Research (8 papers). Meena Okera is often cited by papers focused on Advanced Breast Cancer Therapies (21 papers), Cancer Treatment and Pharmacology (11 papers) and HER2/EGFR in Cancer Research (8 papers). Meena Okera collaborates with scholars based in Australia, United States and Spain. Meena Okera's co-authors include Masakazu Toi, George W. Sledge, Eva‐Maria Grischke, Joohyuk Sohn, Peter A. Kaufman, Norikazu Masuda, Xavier Pivot, Han Koh, Patrick Neven and Antonio Llombart‐Cussac and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Meena Okera

29 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

2017 1.1k citations George W. Sledge, Masakazu Toi et al. Journal of Clinical Oncology profile →
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

2019 590 citations George W. Sledge, Masakazu Toi et al. JAMA Oncology profile →

Peers

Countries citing papers authored by Meena Okera

Since Specialization

Citations

This map shows the geographic impact of Meena Okera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meena Okera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meena Okera more than expected).

Fields of papers citing papers by Meena Okera

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meena Okera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meena Okera. The network helps show where Meena Okera may publish in the future.

Co-authorship network of co-authors of Meena Okera

This figure shows the co-authorship network connecting the top 25 collaborators of Meena Okera. A scholar is included among the top collaborators of Meena Okera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meena Okera. Meena Okera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2− advanced or metastatic breast cancer: phase 1/2 study results 2025 ·Breast Cancer Research ·Erika Hamilton, Manish Patel, Virginia F. Borges, Jane Meisel, Meena Okera, Carlos Alemany, Timothy Pluard, (unknown), Dhanusha Sabanathan, Kathy D. Miller, Alison Conlin, Nicole McCarthy, (unknown), Margaret Tonda, Mark Shilkrut, Nancy U. Lin	2
2	Final Overall Survival Analysis of MONARCH 2: A Phase 3 Trial of Abemaciclib plus Fulvestrant in Patients with Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer 2023 ·Senologie - Zeitschrift für Mammadiagnostik und -therapie ·Eva‐Maria Grischke, Antonio Llombart‐Cussac, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Pierfranco Conté, Valérie André, Fang Bian, Ashwin Shahir, (unknown), George W. Sledge	1
3	382MO Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer 2023 ·Annals of Oncology ·Nancy U. Lin, Virginia F. Borges, Manish R. Patel, Meena Okera, Jane Meisel, Robert Wesolowski, Timothy Pluard, Kathy D. Miller, Nicole McCarthy, Alison Conlin, Reshma Mahtani, Dhanusha Sabanathan, Kelly McCann, (unknown), (unknown), Joerg H. Schroeder, Erika Hamilton	7
4	187O Capivasertib and fulvestrant for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Subgroup analyses from the phase III CAPItello-291 trial 2023 ·ESMO Open ·Mafalda Oliveira, H. S. Rugo, Sacha J. Howell, Florence Dalenc, Javier Cortés, Henry Gómez, Xin Hu, Komal Jhaveri, Sibylle Loibl, Serafín Morales, Meena Okera, Y.H. Park, Joohyuk Sohn, Eriko Tokunaga, Lyudmila Zhukova, (unknown), Gaia Schiavon, Andrew Foxley, Nicholas C. Turner	5
5	Abstract GS3-04: GS3-04 Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial 2023 ·Cancer Research ·Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell, Florence Dalenc, Javier Cortés, Henry Gómez, Xichun Hu, Komal Jhaveri, Sibylle Loibl, Serafín Morales, Zbigniew Nowecki, Meena Okera, (unknown), Masakazu Toi, Lyudmila Zhukova, (unknown), Gaia Schiavon, Andrew Foxley, Hope S. Rugo	23
6	Abstract PD13-11: PD13-11 Final Overall Survival Analysis of Monarch 2 : A Phase 3 trial of Abemaciclib Plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer 2023 ·Cancer Research ·Antonio Llombart‐Cussac, George W. Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Eva‐Maria Grischke, Pierfranco Conté, Valérie André, (unknown), Ashwin Shahir, (unknown)	11
7	An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer 2022 ·Breast Cancer Research and Treatment ·Elgene Lim, Frances Boyle, Meena Okera, Sherene Loi, Sema Sezgin Göksu, (unknown), Sonya C. Chapman, (unknown), Yanyun Chen, Gregory L. Price, Anwar M. Hossain, M. Corona Gainford, (unknown)	4
8	Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials 2021 ·Breast Cancer Research and Treatment ·Matthew P. Goetz, Meena Okera, Hans Wildiers, Mario Campone, Eva‐Maria Grischke, Luís Manso, Valérie André, Nadia Chouaki, Belén San Antonio, Masakazu Toi, George W. Sledge	34
9	MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer 2021 ·Clinical Cancer Research ·Patrick Neven, Stephen Johnston, Masakazu Toi, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Eva‐Maria Grischke, Pierfranco Conté, Yi Lu, Nadine Haddad, Karla Hurt, Antonio Llombart‐Cussac, George W. Sledge	7
10	Abstract P5-14-05: The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study 2020 ·Cancer Research ·Elgene Lim, Frances Boyle, Meena Okera, Sherene Loi, Sema Sezgin Göksu, (unknown), (unknown), (unknown), Gregory L. Price, Anwar Hossain, M. Corona Gainford, (unknown)	1
11	MONARCH 2: Subgroup analysis of patients receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer. 2020 ·Journal of Clinical Oncology ·Patrick Neven, Stephen Johnston, Masakazu Toi, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Han Koh, Eva‐Maria Grischke, Pierfranco Conté, Yi Lu, Nadine Haddad, Karla Hurt, Peter A. Kaufman, Antonio Llombart‐Cussac, George W. Sledge	2
12	The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 breakdown → 2019 ·JAMA Oncology ·George W. Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Eva‐Maria Grischke, Pierfranco Conté, Yi Lu, Susana Barriga, Karla Hurt, Martin Frenzel, Stephen Johnston, Antonio Llombart‐Cussac	590
13	An open‐label, dose‐ranging study of Rolontis, a novel long‐acting myeloid growth factor, in breast cancer 2018 ·Cancer Medicine ·Jeffrey Vacirca, Arlene Chan, (unknown), (unknown), Zsuzsanna Pápai, Kimberly McGregor, Meena Okera, Zsolt Horváth, László Landherr, (unknown), Steven Hager, Emad Ibrahim, (unknown), Gajanan Bhat, Mi Rim Choi, (unknown), Karen L. Tedesco, Richy Agajanian, István Láng, Lee S. Schwartzberg	10
14	MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy breakdown → 2017 ·Journal of Clinical Oncology ·George W. Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Eva‐Maria Grischke, Martin Frenzel, Yong Lin, Susana Barriga, Ian C. P. Smith, Nawel Bourayou, Antonio Llombart‐Cussac	1103
15	Multinational study exploring patients’ perceptions of side-effects induced by chemo-radiotherapy 2015 ·Radiotherapy and Oncology ·Christina H. Ruhlmann, Trine Zeeberg Iversen, Meena Okera, Aida Muhic, Gunnar B. Kristensen, Petra Feyer, Olfred Hansen, Jørn Herrstedt	22
16	Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma Patients 2014 ·Case Reports in Oncological Medicine ·Stephanie Du Four, Angela Hong, Matthew Chan, (unknown), Johnny Duerinck, Sofie Wilgenhof, Wei Wang, (unknown), Alex Michotte, Meena Okera, Brindha Shivalingam, Gerald B. Fogarty, Richard Kefford, Bart Neyns	33
17	Oncology workforce issues: the challenge of the outpatient clinic 2011 ·Internal Medicine Journal ·Meena Okera, (unknown), (unknown), (unknown)	7
18	The effect of Cockcroft-Gault (CG) measurement of GFR on carboplatin dosage in ovarian cancer patients compared with Cr⁵¹-EDTA. 2011 ·Journal of Clinical Oncology ·Meena Okera, (unknown), (unknown), (unknown)	1
19	Evaluation of nuclear factor κB and chemokine receptor CXCR4 co‐expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610 2010 ·British Journal of Urology ·Meena Okera, (unknown), Eric Bernstein, Liang Cheng, C.A. Lawton, Harvey B. Wolkov, Alan Pollack, Adam P. Dicker, Howard M. Sandler, Christopher J. Sweeney	17
20	A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings 2010 ·British Journal of Cancer ·Meena Okera, (unknown), (unknown), James Larkin, Sanjay Popat, Duncan C. Gilbert, (unknown), Nnenna Osuji, (unknown), Catherine Oakley, (unknown), (unknown), S. Chowdhury	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact